Spots Global Cancer Trial Database for Maintenance Gemcitabine in the Chinese Advanced Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Maintenance Gemcitabine in the Chinese Advanced Lung Cancer
Official Title: Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin
Study ID: NCT01336192
Conditions
Study Description
Brief Summary: Lung cancer, the most common cancer worldwide, remains the leading cause of cancer death. Approximately two-thirds of all patients with newly diagnosed non-small-cell lung cancer (NSCLC) present with advanced stage that palliative chemotherapy is the only appropriate measure. The standard treatment for this patient population consists of third generation platinum-based doublet regimen for no more than 6 cycles followed by watch and wait until disease progression (PD) before the administration of second-line and third-line systemic anticancer therapeutic agents. Patients who go on to receive second-line therapy represent a selected subgroup with an improved overall prognosis. Switch maintenance therapy with pemetrexed or erlotinib in patients with advanced NSCLC without PD after first-line chemotherapy has been confirmed to improve progression free survival (PFS) and overall survival (OS) significantly compared with placebo in two large randomized controlled studies. However, continuation gemcitabine maintenance therapy in this setting yields conflicting results in the west, i.e.showing a prolongation of PFS without OS improvement. Thus, we investigate the efficacy and safety of continuation of gemcitabine maintenance therapy for patients with metastatic NSCLC with ECOG performance status of 0-1 and without PD after four cycles of first-line chemotherapy with gemcitabine and cisplatin in China.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Shanghai Pulmonary Hospital Medical Oncology Department, Shanghai, Shanghai, China
Contact Details
Name: Di Zheng, MD
Affiliation: Shanghai Pulmonary Hospital, Shanghai, China
Role: PRINCIPAL_INVESTIGATOR
Name: Wen Gao, MD
Affiliation: Shanghai Pulmonary Hospital, Shanghai, China
Role: STUDY_CHAIR
Name: Jianfang Xu, MD
Affiliation: Shanghai Pulmonary Hosptial
Role: STUDY_DIRECTOR
Name: Li Wang, MD
Affiliation: Shanghai Pulmonary Hospital, Shanghai, China
Role: STUDY_DIRECTOR
Name: Meijun Lv, MD
Affiliation: Shanghai Pulmonary Hospital, Shanghai, China
Role: STUDY_DIRECTOR
Name: Jian Ni, MD
Affiliation: Shanghai Pulmonary Hospital, Shanghai, China
Role: STUDY_DIRECTOR
Name: Jie Zhang, MD
Affiliation: Shanghai Pulmonary Hospital, Shanghai, China
Role: STUDY_DIRECTOR
Name: Bing Lu, MD
Affiliation: Shanghai Pulmonary Hospital, Shanghai, China
Role: STUDY_DIRECTOR
Name: Ying Xu, MD
Affiliation: Shanghai Pulmonary Hospital, Shanghai, China
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
